A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Subjects With Myelodysplastic Syndromes
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Incidence of dose-limiting toxicity in accordance with Common Terminology Criteria for Adverse Events
Incidence of dose-limiting toxicity in accordance with Common Terminology Criteria for Adverse Events
1 month
Yes
Masamitsu Harata
Study Director
Celgene K.K.
Japan: Pharmaceuticals and Medical Devices Agency
AZA-MDS-005
NCT01571648
April 2012
January 2013
Name | Location |
---|